Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nutritional Therapeutics

This article was originally published in The Tan Sheet

Executive Summary

Hauppauge, N.Y.-based manufacturer funding two clinical trials studying the effects of its Propax dietary supplement on chemotherapy-related, quality-of-life factors in cancer patients. NTI says Propax provides "premium nutritional support" with vitamins, minerals, amino acids, essential fatty acids, antioxidants and probiotics. Enrollment of 60 patients in a double-blind, placebo-controlled crossover study at Harbor-UCLA Medical Center is under way, and will run two-and-a-half months. An open label, non-crossover study following 40 patients over a 60-day period is slated to commence at the East Texas Medical Center Healthcare System this fall. The American Nutraceutical Association is coordinating the studies
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS090286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel